Author

A. Molinolo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. H. Baker· 1 shared A. M. Barrie· 1 shared A. M. Mark· 1 shared B. A. Scheven· 1 shared B. Gyorffy· 1 shared B. Van Espen· 1 shared C. Collins· 1 shared C. J. Diaz Osterman· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. H. Baker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential.

B. Van Espen, H. Z. Oo, C. Collins, L. Fazil, A. Molinolo, R. Murad, M. Gleave, Z. A. Ronai

This study shows RNF185 limits prostate cancer migration and metastasis by controlling COL3A1 expression.

bioRxiv · Jun 29, 2023Cancer Biology

The common analgesic paracetamol enhances the anti-tumour activity of decitabine through exacerbation of oxidative stress

H. J. Gleneadie, A. H. Baker, N. Batis, J. Bryant, Y. Jiang, S. J. Clokie, H. Mehanna, P. Garcia, D. M. Gendoo, S. Roberts, A. Molinolo, S. Gutkind, B. A. Scheven, P. R. Cooper, F. Khanim, M. Wiench

This study shows that paracetamol enhances decitabine's anti-tumour effects by increasing oxidative stress without worsening DNA damage.

bioRxiv · Mar 31, 2020 · PreprintCancer Biology

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

C. J. Diaz Osterman, D. Ozmadenci, E. G. Kleinschmidt, K. N. Taylor, A. M. Barrie, S. Jiang, L. M. Bean, F. J. Sulzmaier, C. Jean, I. Tancioni, K. Anderson, S. Uryu, E. A. Cordasco, J. Li, X. L. Chen, , D. D. Schlaepfer

This study identifies FAK activity as a driver of platinum resistance in ovarian cancer by sustaining CSC survival and DNA repair, showing that FAK inhibitors combined with platinum can overcome resistance.

bioRxiv · Mar 30, 2019Cancer Biology